LEADING LABORATORY QUALITY

LEADING LABORATORY QUALITY

LEADING LABORATORY QUALITY

PATIENTS CAN REST ASSURED THAT THEIR RESULTS ARE ACCURATE BECAUSE OF THE CAP’S INNOVATION AND COMMITMENT TO QUALITY IN LABORATORY MEDICINE.

PATIENTS CAN REST ASSURED THAT THEIR RESULTS ARE ACCURATE BECAUSE OF THE CAP’S INNOVATION AND COMMITMENT TO QUALITY IN LABORATORY MEDICINE.

CAP Ensures Laboratory Excellence

Laboratory medicine is changing at a rapid pace. The CAP’s comprehensive range of laboratory quality solutions constantly evolves to keep in step with these changes, enabling more time for what matters most—accuracy in the laboratory.

Year over year the CAP innovates, drawing on the collective knowledge of thousands of member experts to help laboratories navigate the accelerating changes in laboratory medicine and health care. Much of this innovation comes from integrated laboratory quality solutions that include accreditation and PT. These programs ensure the highest quality of patient care and mitigate risk for laboratories and the patients they serve.

CAP Ensures Laboratory Excellence

Laboratory medicine is changing at a rapid pace. The CAP’s comprehensive range of laboratory quality solutions constantly evolves to keep in step with these changes, enabling more time for what matters most—accuracy in the laboratory.

Year over year the CAP innovates, drawing on the collective knowledge of thousands of member experts to help laboratories navigate the accelerating changes in laboratory medicine and health care. Much of this innovation comes from integrated laboratory quality solutions that include accreditation and PT. These programs ensure the highest quality of patient care and mitigate risk for laboratories and the patients they serve.

CAP Ensures Laboratory Excellence

Laboratory medicine is changing at a rapid pace. The CAP’s comprehensive range of laboratory quality solutions constantly evolves to keep in step with these changes, enabling more time for what matters most—accuracy in the laboratory.

Year over year the CAP innovates, drawing on the collective knowledge of thousands of member experts to help laboratories navigate the accelerating changes in laboratory medicine and health care. Much of this innovation comes from integrated laboratory quality solutions that include accreditation and PT. These programs ensure the highest quality of patient care and mitigate risk for laboratories and the patients they serve.

CAP Provides Global Laboratory Leadership

More than 22,000 laboratories worldwide chose the CAP as their PT provider. The CAP launched 28 new programs in 2018, bolstering its comprehensive suite of 650 PT programs that offer innovative and scientifically developed PT for both routine and esoteric testing. Seven new programs were designed specifically for quality assurance in next-generation sequencing, including emerging areas such as cell-free circulating tumor DNA testing and noninvasive prenatal testing.

The CAP’s innovation carried through to its Laboratory Accreditation Program, a vital part of providing high-quality patient care. CAP-accredited laboratories, numbering more than 8,000 worldwide, are committed to quality improvement beyond simply satisfying regulatory requirements. They see CAP accreditation as an opportunity to pursue continuous improvement in patient care.

CAP Provides Global Laboratory Leadership

More than 22,000 laboratories worldwide chose the CAP as their PT provider. The CAP launched 28 new programs in 2018, bolstering its comprehensive suite of 650 PT programs that offer innovative and scientifically developed PT for both routine and esoteric testing. Seven new programs were designed specifically for quality assurance in next-generation sequencing, including emerging areas such as cell-free circulating tumor DNA testing and noninvasive prenatal testing.

The CAP’s innovation carried through to its Laboratory Accreditation Program, a vital part of providing high-quality patient care. CAP-accredited laboratories, numbering more than 8,000 worldwide, are committed to quality improvement beyond simply satisfying regulatory requirements. They see CAP accreditation as an opportunity to pursue continuous improvement in patient care.

CAP Provides Global Laboratory Leadership

More than 22,000 laboratories worldwide chose the CAP as their PT provider.

The CAP launched 28 new programs in 2018, bolstering its comprehensive suite of 650 PT programs that offer innovative and scientifically developed PT for both routine and esoteric testing. Seven new programs were designed specifically for quality assurance in next-generation sequencing, including emerging areas such as cell-free circulating tumor DNA testing and noninvasive prenatal testing.

The CAP’s innovation carried through to its Laboratory Accreditation Program, a vital part of providing high-quality patient care. CAP-accredited laboratories, numbering more than 8,000 worldwide, are committed to quality improvement beyond simply satisfying regulatory requirements. They see CAP accreditation as an opportunity to pursue continuous improvement in patient care.

Accreditation Checklists Set Standards for Quality Laboratory Practices

Twenty-one discipline-specific Laboratory Accreditation Program checklists with nearly 3,000 requirements form the quality practices blueprint for laboratories to:

  • Maintain compliance with Centers for Medicare & Medicaid Services (CMS) regulations
  • Stay up to date with changes in laboratory medicine

The CAP updates its accreditation checklists every year, renewing the CAP’s promise to help laboratory partners administer world-class patient care. The collective knowledge of the CAP’s scientific resource committees reflects changing technology and increasing sophistication in laboratory testing.

In the 2018 accreditation checklist edition, the CAP added more than 40 new requirements and significantly revised approximately 240 requirements, with the most significant changes in the Anatomic Pathology Checklist, Laboratory General Checklist, and Transfusion Medicine Checklist.

Laboratory quality solutions include much more, extending to the CAP’s leadership in the development of cancer protocols and evidence-based guidelines and in tracking advancements in technology.

3d illustration of a cancer cell in the process of mitosis

Accreditation Checklists Set Standards for Quality Laboratory Practices

Twenty-one discipline-specific Laboratory Accreditation Program checklists with nearly 3,000 requirements form the quality practices blueprint for laboratories to:

  • Maintain compliance with Centers for Medicare & Medicaid Services (CMS) regulations
  • Stay up to date with changes in laboratory medicine

The CAP updates its accreditation checklists every year, renewing the CAP’s promise to help laboratory partners administer world-class patient care. The collective knowledge of the CAP’s scientific resource committees reflects changing technology and increasing sophistication in laboratory testing.

In the 2018 accreditation checklist edition, the CAP added more than 40 new requirements and significantly revised approximately 240 requirements, with the most significant changes in the Anatomic Pathology Checklist, Laboratory General Checklist, and Transfusion Medicine Checklist.

Laboratory quality solutions include much more, extending to the CAP’s leadership in the development of cancer protocols and evidence-based guidelines and in tracking advancements in technology.

3d illustration of a cancer cell in the process of mitosis

Accreditation Checklists Set Standards for Quality Laboratory Practices

Twenty-one discipline-specific Laboratory Accreditation Program checklists with nearly 3,000 requirements form the quality practices blueprint for laboratories.

These checklists help laboratories:

  • Maintain compliance with Centers for Medicare & Medicaid Services (CMS) regulations
  • Stay up to date with changes in laboratory medicine

The CAP updates its accreditation checklists every year, renewing the CAP’s promise to help laboratory partners administer world-class patient care. The collective knowledge of the CAP’s scientific resource committees reflects changing technology and increasing sophistication in laboratory testing.

3d illustration of a cancer cell in the process of mitosis

In the 2018 accreditation checklist edition, the CAP added more than 40 new requirements and significantly revised approximately 240 requirements, with the most significant changes in the Anatomic Pathology Checklist, Laboratory General Checklist, and Transfusion Medicine Checklist.

Laboratory quality solutions include much more, extending to the CAP’s leadership in the development of cancer protocols and evidence-based guidelines and in tracking advancements in technology.

Cancer Protocols, Biomarker Templates, and eFRM Tools Improve Reportability

In 2018, the Cancer and Pathology Electronic Reporting committees released 54 revised cancer protocols and biomarker templates, in addition to the new DNA Mismatch Repair biomarker template aligned with checkpoint inhibitor immunotherapy testing. While most updates were minor, significant revisions improved the reportability of regional lymph nodes and the redesign of the Central Nervous System protocol to allow for reporting initial findings and then for reporting biomarkers with an integrated diagnosis.

More than 5,200 pathologists are now licensed to use the electronic Cancer Checklists (eCC) and the CAP electronic Forms and Reporting Module (eFRM) tools for cancer reporting in their laboratory information system and workflow.

In addition, in 2018 the Centers for Disease Control and Prevention (CDC) awarded the CAP a five-year, $300,000/year collaborative grant to further address standardization and support for diagnostic cancer and biomarker electronic reporting. This initiative supports continued eCC product development, including technical and functional improvements, pathologist and cancer registrar educational activities, and promotion of downstream data usage for quality reporting and surveillance activities.

Cancer Protocols, Biomarker Templates, and eFRM Tools Improve Reportability

In 2018, the Cancer and Pathology Electronic Reporting committees released 54 revised cancer protocols and biomarker templates, in addition to the new DNA Mismatch Repair biomarker template aligned with checkpoint inhibitor immunotherapy testing. While most updates were minor, significant revisions improved the reportability of regional lymph nodes and the redesign of the Central Nervous System protocol to allow for reporting initial findings and then for reporting biomarkers with an integrated diagnosis.

More than 5,200 pathologists are now licensed to use the electronic Cancer Checklists (eCC) and the CAP electronic Forms and Reporting Module (eFRM) tools for cancer reporting in their laboratory information system and workflow.

In addition, in 2018 the Centers for Disease Control and Prevention (CDC) awarded the CAP a five-year, $300,000/year collaborative grant to further address standardization and support for diagnostic cancer and biomarker electronic reporting. This initiative supports continued eCC product development, including technical and functional improvements, pathologist and cancer registrar educational activities, and promotion of downstream data usage for quality reporting and surveillance activities.

Cancer Protocols, Biomarker Templates, and eFRM Tools Improve Reportability

In 2018, the Cancer and Pathology Electronic Reporting committees released 54 revised cancer protocols and biomarker templates, in addition to the new DNA Mismatch Repair biomarker template aligned with checkpoint inhibitor immunotherapy testing.

While most updates were minor, significant revisions improved the reportability of regional lymph nodes and the redesign of the central nervous system protocol to allow for reporting initial findings and then for reporting biomarkers with an integrated diagnosis.

More than 5,200 pathologists are now licensed to use the electronic Cancer Checklists (eCC) and the CAP electronic Forms and Reporting Module (eFRM) tools for cancer reporting in their laboratory information system and workflow.

In addition, in 2018 the Centers for Disease Control and Prevention (CDC) awarded the CAP a five-year, $300,000/year collaborative grant to further address standardization and support for diagnostic cancer and biomarker electronic reporting. This initiative supports continued eCC product development, including technical and functional improvements, pathologist and cancer registrar educational activities, and promotion of downstream data usage for quality reporting and surveillance activities.

Evidence-Based Guidelines Advance Pathology

The CAP’s Pathology and Laboratory Quality Center for Evidence-Based Guidelines (the Center) collaborated or partnered with more than 10 professional societies and patient advocacy organizations this past year. Joint efforts such as these ensure that the practice of pathology is fully represented and its practitioners are seen as invaluable members of the clinical care team. The CAP is committed to advancing the specialty by developing evidence-based guidelines and bringing them to the forefront of clinical decision making.

Along with its partners, the Center published two evidence-based guidelines in 2018:

  1. The CAP/International Association for the Study of Lung Cancer (IASLC)/Association for Molecular Pathology (AMP) update of the “Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors” recommends testing for new genes such as ROS1 mutations.
  2. The American Society of Clinical Oncology (ASCO)/CAP focused update on “Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer” offers a revised definition of IHC 2+ score classification of the less common patterns observed when performing dual-probe ISH testing for breast cancer and the optimal algorithm for the diagnostic approach.

The Center wrapped up the five-year, CDC-funded grant “Improving the Impact of Laboratory Practice: A New Paradigm for Metrics.” As a result, the Center identified sustainable modalities to track metrics and established new collaboration relationship models. In addition, the Center created and revised processes to improve guideline development and dissemination to increase awareness, adoption, and implementation.

Evidence-Based Guidelines Advance Pathology

The CAP’s Pathology and Laboratory Quality Center for Evidence-Based Guidelines (the Center) collaborated or partnered with more than 10 professional societies and patient advocacy organizations this past year. Joint efforts such as these ensure that the practice of pathology is fully represented and its practitioners are seen as invaluable members of the clinical care team. The CAP is committed to advancing the specialty by developing evidence-based guidelines and bringing them to the forefront of clinical decision making.

Along with its partners, the Center published two evidence-based guidelines in 2018:

  1. The CAP/International Association for the Study of Lung Cancer (IASLC)/Association for Molecular Pathology (AMP) update of the “Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors” recommends testing for new genes such as ROS1 mutations.
  2. The American Society of Clinical Oncology (ASCO)/CAP focused update on “Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer” offers a revised definition of IHC 2+ score classification of the less common patterns observed when performing dual-probe ISH testing for breast cancer and the optimal algorithm for the diagnostic approach.

The Center wrapped up the five-year, CDC-funded grant “Improving the Impact of Laboratory Practice: A New Paradigm for Metrics.” As a result, the Center identified sustainable modalities to track metrics and established new collaboration relationship models. In addition, the Center created and revised processes to improve guideline development and dissemination to increase awareness, adoption, and implementation.

Evidence-Based Guidelines Advance Pathology

The CAP’s Pathology and Laboratory Quality Center for Evidence-Based Guidelines (the Center) collaborated or partnered with more than 10 professional societies and patient advocacy organizations this past year.

Joint efforts such as these ensure that the practice of pathology is fully represented and its practitioners are seen as invaluable members of the clinical care team. The CAP is committed to advancing the specialty by developing evidence-based guidelines and bringing them to the forefront of clinical decision making.

Along with its partners, the Center published two evidence-based guidelines in 2018:

  1. The CAP/International Association for the Study of Lung Cancer (IASLC)/Association for Molecular Pathology (AMP) update of the “Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors” recommends testing for new genes such as ROS1 mutations.
  2. The American Society of Clinical Oncology (ASCO)/CAP focused update on “Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer” offers a revised definition of IHC 2+ score classification of the less common patterns observed when performing dual-probe ISH testing for breast cancer and the optimal algorithm for the diagnostic approach.

The Center wrapped up the five-year, CDC-funded grant “Improving the Impact of Laboratory Practice: A New Paradigm for Metrics.” As a result, the Center identified sustainable modalities to track metrics and established new collaboration relationship models. In addition, the Center created and revised processes to improve guideline development and dissemination to increase awareness, adoption, and implementation.

Technology Advances Help Shape the Pathologist’s Future

The CAP keeps a close eye on innovation as it happens at a faster rate than ever before in laboratory medicine due to technological advancements. Recognizing the vast amounts of data generated by laboratories, technology companies are developing new artificial intelligence (AI) and machine learning tools that create both opportunities and challenges for the pathologist. The Informatics Committee and other Council on Scientific Affairs (CSA) committees analyze the developments in this area, while providing new resources to inform the pathology community about these advancements. The CSA and the Council on Government and Professional Affairs (CGPA) work together to address regulatory concerns around AI and machine learning, providing the pathologist’s perspective in shaping the future.

Technology Advances Help Shape the Pathologist’s Future

The CAP keeps a close eye on innovation as it happens at a faster rate than ever before in laboratory medicine due to technological advancements. Recognizing the vast amounts of data generated by laboratories, technology companies are developing new artificial intelligence (AI) and machine learning tools that create both opportunities and challenges for the pathologist. The Informatics Committee and other Council on Scientific Affairs (CSA) committees analyze the developments in this area, while providing new resources to inform the pathology community about these advancements. The CSA and the Council on Government and Professional Affairs (CGPA) work together to address regulatory concerns around AI and machine learning, providing the pathologist’s perspective in shaping the future.

Technology Advances Help Shape the Pathologist’s Future

The CAP keeps a close eye on innovation as it happens at a faster rate than ever before in laboratory medicine due to technological advancements.

Recognizing the vast amounts of data generated by laboratories, technology companies are developing new artificial intelligence (AI) and machine learning tools that create both opportunities and challenges for the pathologist. The Informatics Committee and other Council on Scientific Affairs (CSA) committees analyze the developments in this area, while providing new resources to inform the pathology community about these advancements. The CSA and the Council on Government and Professional Affairs (CGPA) work together to address regulatory concerns around AI and machine learning, providing the pathologist’s perspective in shaping the future.

LIVING OUR QUALITY MISSION

LIVING OUR QUALITY MISSION

LIVING OUR QUALITY MISSION

8,053

CAP-accredited laboratories

8,053

CAP-accredited laboratories

2,182

pathologists participating in on-site inspections

2,182

pathologists participating in on-site inspections

22,576

laboratories using the CAP’s proficiency testing

22,576

laboratories using the CAP’s proficiency testing